Barclays Sticks to Its Buy Rating for PDD Holdings (PDD)
Barclays analyst Jiong Shao reiterated a Buy rating on PDD Holdings (PDD – Research Report) today and set a price target of $158.00. The company's shares closed today at $102.98.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Shao covers the Consumer Cyclical sector, focusing on stocks such as Sea, JD, and BYD Co. According to TipRanks, Shao has an average return of 12.5% and a 53.93% success rate on recommended stocks.
Currently, the analyst consensus on PDD Holdings is a Moderate Buy with an average price target of $141.74, implying a 37.64% upside from current levels. In a report released today, Citi also maintained a Buy rating on the stock with a $152.00 price target.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Barclays Rises 32.3% YTD: Is it the Right Time to Buy the Stock?
Year to date, shares of Barclays PLC BCS have risen 32.3%. The stock has outperformed the S&P 500 index, the Zacks Finance sector, and the industry. Meanwhile, it has underperformed its close peer, Deutsche Bank DB, while outperforming HSBC Holdings PLC HSBC. Year-to-Date Price Performance Image Source: Zacks Investment Research However, lingering uncertainty around tariff policies continues to pose risks. Given this backdrop, let's assess whether Barclays stock is a lucrative bet or not. Restructuring Efforts to Boost Profitability: Barclays has been taking steps to divest unprofitable/less profitable operations and save expenses through business streamlining, while deploying capital into higher revenue-generating February 2025, Barclays sold its consumer finance business in Germany. Last year, the company transformed its operating divisions and divested its Italian mortgage portfolio and $1.1 billion in credit card these efforts, Barclays recorded gross savings of £1 billion in 2024 and £150 million in the first quarter of 2025. The company aims to achieve gross efficiency savings of £0.5 billion this year. By 2026, management expects total gross efficiency savings to be £2 billion and the cost-to-income ratio to be in the high 50s. Its first-quarter 2025 cost-to-income ratio was 57%.The company is investing these savings in high-growth businesses and markets. This April, Barclays entered into a collaboration with Brookfield Asset Management Ltd. to reshape its payment acceptance business with plans to inject roughly £400 million. In March, the bank had announced a capital injection of more than INR2,300 crore (£210 million) into its India operations, following an injection of almost INR3,000 crore (£300 million) in 2021. Last year, the company acquired Tesco's retail banking business, which complements its existing business. In 2023, Barclays acquired Kensington Mortgage, which bolstered its mortgage redeployment of capital into higher-growth businesses and markets through improving efficiency is a multifaceted approach to boosting profitability. Barclays remains committed to this approach, which is likely to help improve profitability over Capital Distributions: As of March 31, 2025, Barclays' liquidity coverage ratio and net stable funding ratio were 175.3% and 136.2%, respectively, well above the regulatory requirements. This indicates a solid liquidity and funding profile. Thus, a solid balance sheet position supports its enhanced capital company has been paying dividends regularly and plans to keep the total dividend payout stable at the 2023 level, with progressive dividend plans to return at least £10 billion of capital to shareholders between 2024 and 2026 through dividends and share buybacks, with a continued preference for bank has increased dividends six times in the past five years with an annualized growth rate of 45.04%. It has a dividend payout ratio of 28%. Barclays Dividend Yield Image Source: Zacks Investment Research Over the past two months, the Zacks Consensus Estimate for 2025 earnings per share has been revised 6.2% and 3% upward to $2.23 and $2.73, respectively. Estimate Revision Trend Image Source: Zacks Investment Research The Zacks Consensus Estimate for Barclays' 2025 and 2026 earnings implies year-over-year growth of 21.2% and 22.6%, respectively. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) BCS stock is currently trading at a forward 12-month price/earnings (P/E) of 7.17X. This is below the industry's 9.4X, reflecting an attractive valuation. Price-to-Earnings F12M Image Source: Zacks Investment Research On the other hand, Deutsche Bank and HSBC have a forward P/E of 8.31X and 8.64X, respectively. This reflects that Barclays is trading at a discount compared to its peers. Entering 2025, a major rebound in mergers and acquisitions (M&As) was expected, with deal-making activities likely to grow in the mid-20s. This optimism stemmed from pent-up demand, stabilizing or declining interest rates, tightening credit spreads, and strong public market valuations. Also, the Trump administration was perceived as business-friendly, with an expected removal of stringent oversight that could mark the end of the prolonged regulatory of these has transpired till now. Deal-making activities have been muted as ambiguity over the tariff and ensuing trade war has resulted in extreme market volatility. These developments have led to economic uncertainty. Against such a backdrop, companies are rethinking their M&A plans despite stabilizing rates and having significant investible management expects investment banking risk-weighted assets (RWAs) to be 50% of the Group RWAs in 2026. Further, the delay in the M&A rebound will impact the IB business of other global banks, including HSBC and Deutsche Bank, impacting revenue growth to some extent. Barclays' restructuring efforts to boost efficiency and redeployment of capital to higher revenue-generating businesses are likely to help the company's financials. Further, a solid liquidity profile enables sustainable capital distributions. Bullish analyst sentiments and attractive valuations are other the bank's core operating performance remains a concern. Net interest income (NII) and net fee, commission, and other income have been witnessing a volatile trend over the last several quarters owing to a tough operating backdrop. Though NII and net fee, commission, and other income rose in 2024 and in the first quarter of 2025, in light of structural hedges and Tesco bank buyout, the uncertainty about the performance of the capital markets might weigh on the company's top line, which makes us apprehensive about its growth prospects. Further, the likelihood of a significant IB rebound this year remains low amid concerns regarding tariff policies, making BCS stock a cautious shareholders may benefit from holding for strong long-term returns, while potential investors should wait for greater macroeconomic clarity before taking a currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Barclays PLC (BCS) : Free Stock Analysis Report Deutsche Bank Aktiengesellschaft (DB) : Free Stock Analysis Report HSBC Holdings plc (HSBC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Yahoo
Citi sees Gilead clinical holds as only ‘minor setback'
Citi analyst Geoff Meacham keeps a Buy rating on Gilead (GILD) with a $125 price target after the company announced a clinical hold on its Phase 2 WONDERS trials evaluating the combination of GS-1720 and GS-4182 for once-weekly oral HIV treatment. The hold was initiated due to safety concerns, specifically decreases in CD4+ T-cell and absolute lymphocyte counts observed in a subset of participants receiving the combination therapy, the analyst tells investors in a research note. Citi says the setback impacts the targeted commercial launch of the GS-1720/GS-4182 regimen, previously anticipated in 2029 or 2030. The hold does not affect Gilead's other ongoing HIV programs, including lenacapavir development for both treatment and prevention including the monthly oral combinations, as no similar lymphocyte or CD4 effects have been observed in these studies, Citi points out. As such, the firm sees the holds as a 'minor setback' and continues to believe that lenacapavir in pre-exposure prophylaxis and expansion of several differentiated lenacapavir combos should offset potential Biktarvy 2028 Inflation Reduction Act negotiations. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on GILD: Disclaimer & DisclosureReport an Issue FDA placed clinical hold on Gilead HIV treatment trials of GS-1720 Gilead down 2% to $111.14 after FDA placed hold on some HIV trials Gilead Sciences: Strong Market Position and Growth Potential Drive Buy Rating Gilead Sciences' Oncology Advancements: Trodelvy's Potential to Boost Stock Value Gilead Sciences: Promising Pipeline and Strategic Advancements Justify Buy Rating Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Yahoo
Mixed options sentiment in CrowdStrike Holdings with shares up 0.12%
Mixed options sentiment in CrowdStrike Holdings (CRWD), with shares up 55c, or 0.12%, near $464.94. Options volume relatively light with 5050 contracts traded and calls leading puts for a put/call ratio of 0.48, compared to a typical level near 0.76. Implied volatility (IV30) dropped 0.2 near 35.4,in the bottom quartile of the past year, suggesting an expected daily move of $10.37. Put-call skew steepened, indicating increased demand for downside protection, following a downgrade to In Line at Evercore ISI. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on CRWD: Disclaimer & DisclosureReport an Issue Trump Trade: U.S., China representatives to meet about trade Cardinal Health, Dollar General, Snowflake, Constellation, and CrowdStrike: Trending by Analysts Trump signs Executive Order intended to 'strengthen the nation's cybersecurity' U.S. Layoffs Surge despite Strong Jobs Data as Major Corporations Make Cuts U.S. payrolls rise 139,000, Broadcom reports Q2 beat: Morning Buzz Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
